Search

Your search keyword '"Donnici, Lorena"' showing total 49 results

Search Constraints

Start Over You searched for: Author "Donnici, Lorena" Remove constraint Author: "Donnici, Lorena"
49 results on '"Donnici, Lorena"'

Search Results

1. Antibody-independent protection against heterologous SARS-CoV-2 challenge conferred by prior infection or vaccination

2. Tracking the immune response profiles elicited by the BNT162b2 vaccine in COVID-19 unexperienced and experienced individuals

3. B cell analyses after SARS-CoV-2 mRNA third vaccination reveals a hybrid immunity like antibody response

4. Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody

5. Interferon‐inducible phospholipids govern IFITM3‐dependent endosomal antiviral immunity

6. Nirmatrelvir treatment of SARS‐CoV‐2‐infected mice blunts antiviral adaptive immune responses

7. Mapping of functional SARS-CoV-2 receptors in human lungs establishes differences in variant binding and SLC1A5 as a viral entry modulator of hACE2

8. Anti-spike antibodies and neutralising antibody activity in people living with HIV vaccinated with COVID-19 mRNA-1273 vaccine: a prospective single-centre cohort study

9. COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models

13. Isolation and Characterization of Neutralizing Monoclonal Antibodies from a Large Panel of Murine Antibodies against RBD of the SARS-CoV-2 Spike Protein

14. Isolation and Characterization of Neutralizing Monoclonal Antibodies from a Large Panel of Murine Antibodies against RBD of the SARS-CoV-2 Spike Protein.

15. Author Reply to Peer Reviews of Nirmatrelvir treatment blunts the development of antiviral adaptive immune responses in SARS-CoV-2 infected mice

16. Nirmatrelvir treatment blunts the development of antiviral adaptive immune responses in SARS-CoV-2 infected mice

17. Discovery and antiviral profile of new sulfamoylbenzamide derivatives as HBV capsid assembly modulators

18. Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations

19. COVID-19 mRNA third dose induces a unique hybrid immunity-like antibody response

20. Synthetic carbohydrate-binding agents neutralize SARS-CoV-2 by inhibiting binding of the spike protein to ACE2

21. Anatomy of Omicron neutralizing antibodies in COVID-19 mRNA vaccinees

22. Administration of aerosolized SARS-CoV-2 to K18-hACE2 mice uncouples respiratory infection from fatal neuroinvasion

24. Corrigendum to “DNA aptamers masking angiotensin converting enzyme 2 as an innovative way to treat SARS-CoV-2 pandemic”

25. Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody

26. Integrated longitudinal immunophenotypic, transcriptional, and repertoire analyses delineate immune responses in patients with COVID-19

27. Controlled administration of aerosolized SARS-CoV-2 to K18-hACE2 transgenic mice uncouples respiratory infection and anosmia from fatal neuroinvasion

28. COVID-eVax, an electroporated plasmid DNA vaccine candidate encoding the SARS-CoV-2 Receptor Binding Domain, elicits protective immune responses in animal models of COVID-19

30. Synthetic Carbohydrate Binding Agents (CBAs) Prevent SARS-CoV-2 Entry by Inhibiting Binding of the Spike Protein to the ACE2 Receptor

31. Anti-Spike Antibodies and Neutralising Antibody Activity in People Living with HIV Vaccinated with COVID-19 mRNA-1273 Vaccine: A Prospective Cohort Study

32. Preparation of arylaminocarbonyl bicyclic sulfonamides as inhibitors of hepatitis B virus

33. Preparation of oxalamido-​substituted tricyclic inhibitors of hepatitis B virus

34. Preparation of arylaminocarbonyl pyrrolo-​fused tricyclic sulfonamides as inhibitors of hepatitis B virus

35. Preclinical assessment of capsid assembly modulators (CAMs) of varying potency revealed a novel class of picomolar-acting CAMs inducing neither significant HBcAg cytoplasmic retention nor adverse interactions with HBcAg-specific adaptive immunity

36. Nanoparticle‐Mediated Suicide Gene Therapy for Triple Negative Breast Cancer Treatment

37. Time-dependent biphasic modulation of human BDNF by antidepressants in neuroblastoma cells

39. Hepatitis C Virus Deletion Mutants Are Found in Individuals Chronically Infected with Genotype 1 Hepatitis C Virus in Association with Age, High Viral Load and Liver Inflammatory Activity

40. Interaction between PNPLA3 I148M Variant and Age at Infection in Determining Fibrosis Progression in Chronic Hepatitis C

41. Interleukin 28B genotype and insulin resistance in chronic hepatitis C patients

42. Metabolism of Phosphatidylinositol 4-Kinase IIIα-Dependent PI4P Is Subverted by HCV and Is Targeted by a 4-Anilino Quinazoline with Antiviral Activity

44. Interaction between PNPLA3 I148M Variant and Age at Infection in Determining Fibrosis Progression in Chronic Hepatitis C.

45. Discovery and antiviral profile of new sulfamoylbenzamide derivatives as HBV capsid assembly modulators

46. Administration of aerosolized SARS-CoV-2 to K18-hACE2 mice uncouples respiratory infection from fatal neuroinvasion

48. Preclinical assessment of capsid assembly modulators (CAMs) of varying potency revealed a novel class of picomolar-acting CAMs inducing neither significant HBcAg cytoplasmic retention nor adverse interactions with HBcAg-specific adaptive immunity

49. Integrated longitudinal immunophenotypic, transcriptional and repertoire analyses delineate immune responses in COVID-19 patients.

Catalog

Books, media, physical & digital resources